welcome to DuchenneXchange
- a positively charged Duchenne muscular dystrophy community.- join today!
- login
Avidity Biosciences Receives Investment from CureDuchenne
Avidity Biosciences, a privately held biotech company pioneering a new class of precision medicines based upon antibody-oligonucleotide conjugates, announced today that CureDuchenne has made an equity investment in the company. Funding will help to advance pre-clinical development of potential therapies to treat patients with Duchenne muscular dystrophy (DMD).
rareRelated
-
BIOPHYTIS to Host Key Opinion Leader Meeting on the Biology of Aging and its Application in Neuromuscular DiseasesBiophytis, a clinical-stage biotechnolog...
-
Dame Kay Davies Explains Duchenne Muscular Dystrophy and Her Utrophin Researchhttps://player.vimeo.com/video/172905129...
-
CureDuchenneCureDuchenne is recognized as the global...
-
The PTC124 (Ataluren) Clinical Trial for Duchenne Muscular Dystrophy: Exploration of the Experiences of Parents, Cli...The purpose of this study is to describe...
-
A 48-Week, Open Label, Study to Evaluate the Efficacy and Safety of Casimersen, Eteplirsen and Golodirsen in Subject...This is an 48-week open-label study to d...
-
Therapeutic advances in muscular dystrophyThe muscular dystrophies comprise a hete...
-
Kathryn Wagner, MD, PhD – Progress in Better Treatments for Muscular Dystrophyhttps://www.youtube.com/watch?v=0yC4_lEn...
